NCT Number: NCT04925284
Phase: Phase 1
Trial Summary: This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Exelixis
Acronym:
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives